Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry

AL RAISI, Sara, PROTTY, Majd, RAPOSEIRAS-ROUBÍN, Sergio, D?ASCENZO, Fabrizio, ABU-ASSI, Emad, ARIZA-SOLÉ, Albert, MANZANO-FERNÁNDEZ, Sergio, TEMPLIN, Christian, VELICKI, Lazar, XANTHOPOULOU, Ioanna, CERRATO, Enrico, QUADRI, Giorgio, ROGNONI, Andrea, BOCCUZZI, Giacomo, MONTABONE, Andrea, TAHA, Salma, DURANTE, Alessandro, GILI, Sebastiano, MAGNANI, Giulia, AUTELLI, Michele, GROSSO, Alberto, FLORES-BLANCO, Pedro, VARBELLA, Ferdinando, CESPÓN-FERNÁNDEZ, María, GALLO, Diego, MORBIDUCCI, Umberto, DOMÍNGUEZ-RODRÍGUEZ, Alberto, CEQUIER, Ángel, GAITA, Fiorenzo, ALEXOPOULOS, Dimitrios, VALGIMIGLI, Marco, ÍÑIGUEZ-ROMO, Andrés and KINNAIRD, Tim 2021. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Minerva Cardiology and Angiology 69 (4) , pp. 408-416. 10.23736/S2724-5683.21.05591-5

Full text not available from this repository.

Abstract

BACKGROUND: The use of potent P2Y12 inhibitors (ticagrelor & prasugrel) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) is a class I recommendation. We performed a sex-specific analysis comparing the difference in efficacy and safety outcomes between ticagrelor and prasugrel in a real-world ACS population. METHODS: Data from the multicenter REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) for 4424 ACS patients who underwent PCI and were treated with ticagrelor or prasugrel between 2012 to 2016 were analyzed. Mean follow-up was 17±9 months. RESULTS: After propensity score matching, there was no significant difference in the occurrence of primary endpoint of net adverse cardiac events between ticagrelor and prasugrel in men (HR: 0.94; 95% CI: 0.69-1.29; P=0.71), or women (HR: 1.17; 95% CI: 0.63-2.20; P=0.62; P interaction [sex] = 0.40). Similarly, no differences were found in the occurrence of any of the secondary endpoints (MACE, all cause death, re-infarction, stent thrombosis, BARC major bleeding and BARC any bleeding) between the two P2Y12 groups between men and women. CONCLUSIONS: In this real-world ACS population, no relative difference in efficacy or safety outcomes were found between ticagrelor and prasugrel between sexes.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
ISSN: 2724-5683
Last Modified: 21 Jun 2022 15:45
URI: https://orca.cardiff.ac.uk/id/eprint/150565

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item